RVMDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMDW
Revolution Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$182.15+4.19 (+2.35%)
Close on Oct 19, 2026
- Market cap
- $38.41B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -67.2% | -58.1% | |
| Return on assets | – | -27.5% | -46.1% | |
| Current ratio | – | 9.63 | 7.14 | |
| Interest coverage | – | -1559.1× | -48.8× | |
| Capex to revenue | – | 6.8% | – | |
| Diluted shares | – | 55M | 190M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Revolution Medicines generated $2.18B from operations and spent $51.37M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$2.18B
Used
$51.37M
Capital expenditure$51.37M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3768.3%
×Asset turnover0.01×
×Equity multiplier1.14×
=Return on equity, FY2023-34.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -3768.3% | 0.01× | 1.14× | -34.8% |
| FY2022 | -703.0% | 0.05× | 1.20× | -38.6% |
| FY2021 | -636.6% | 0.05× | 1.21× | -34.7% |
| FY2020 | -251.6% | 0.11× | 2.45× | -67.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$1.13B
- Cash generatingOperating cash flow above zero-$897.74M
- Return on assets improvedROA up on the prior year-29.1% → -44.2%
- Earnings backed by cashOperating cash flow above net income-$897.74M vs -$1.13B
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose14.20 → 7.14
- No dilutionShare count did not rise168M → 190M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00